AI주식인사이트AI Stock Insight
C

동화약품

000020KOSPI의약품 제조업

45.1 / 100

Reference Date: 2026-04-13

Financial Score15.5 / 40
News Sentiment15.6 / 25
Momentum4.0 / 20
Disclosure10.0 / 15
AI Analysis: PBR is significantly undervalued vs. peers but PER raises overvaluation concerns. Slightly down 4.1% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Dongwha Pharm operates in pharmaceuticals, medical device manufacturing and sales, and other financial services. In 2023, sales increased by 6.78% to 496,394 million won compared to the previous year, but operating profit fell by 98.09%. Key subsidiaries include Medissei (medical device manufacturer), TS Care (Vietnam-based pharmaceutical distribution chain), and Dongwha Kripton (venture investment firm).

Number of Employees

838people

Average Salary

71.3M KRW

Score Calculation Basis

Detailed Financial Score

PER
42.74Industry Average 14.800.0Point

2.9x industry avg (risky)

PBR
0.41Industry Average 1.047.0Point

Half of industry avg (excellent)

ROE
0.96Industry Average 4.421.0Point

Well below industry avg

Debt Ratio
9.44Industry Average 11.984.0Point

In line with industry avg

Trend 2023~20253.5 / 10 points
Revenue Growth Rate
2.5 / 3

Avg ▲17.8% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼63.3% (2-year basis)

ROE Trend
1.0 / 4

Avg ROE 2.9% (declining, 3yr)

Detailed News Sentiment

12 totalPositive 3Neutral 4Negative 0Average Sentiment Score 71.4

Detailed Momentum

52-week position1.0Point

Near 52w low (15%, downtrend)

Current 5,880Won52-week high 7,06052-week low 5,660
1-month return2.0Point

1m -4.08% (slight drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0
  • Neutral정기주주총회결과2026-03-26
  • Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-26
  • Neutral감사보고서제출2026-03-18
  • Neutral사업보고서 (2025.12)2026-03-18